Division of Bio-Rad Laboratories Inc.
Latest From QuantaLife Inc.
October’s dealmaking highlights: Biogen received exclusive global rights to Portola’s autoimmune and anti-inflammatory Syk inhibitors in an alliance worth $554 million. Investment firms took public CRO Pharmaceutical Product Development private for $33.25 per share, or a total of $3.9 billion, including debt. Regeneron’s $391 million notes sale propelled the debt category to claim almost half of the $826 million biopharma financing figure. Meantime device companies raised $206 million, mainly from Zeltiq’s $93 million IPO.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bio-Rad Laboratories Inc.
- Senior Management
Bill, Jr. W Colston, PhD, CEO
Paul Kidman, VP, Fin.
Ben Hindson, PhD, CSO
Isaac Bright, MD, VP, Corp. Dev.
- Contact Info
Phone: (925) 474-8600
7068 Koll Center Pkwy.
Pleasanton, CA 94566
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.